Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced the launch of a generic version of Ranexa®1 (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S.
Ranolazine Extended-Release Tablets are indicated for the treatment of chronic angina.
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Ranolazine Extended-Release Tablets has annual sales of nearly $938 million in the U.S., according to IQVIA data as of February 2019. About Ranolazine Extended-Release Tablets Ranolazine Extended-Release Tablets are indicated for the treatment of chronic angina. Ranolazine Extended-Release Tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. IMPORTANT SAFETY INFORMATION Ranolazine Extended-Release Tablets are contraindicated in patients taking strong inhibitors of CYP3A; patients taking inducers of CYP3A; and patients with liver cirrhosis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.